Why AI's builders want medicine first: restoring lost function before augmentation
September 27, 2026 · 24 min read
Neuralink, retinal prosthetics and deep brain stimulation researchers all start with patients who have lost something, such as movement, sight or impulse control, and only then talk about enhancement. This medical-first path shows how brain-machine interfaces will likely reach the public: through clinical need, not consumer upgrades.
The rules, numbers and steps worth keeping in front of you.
- Builders start with lost function because the benefit must justify the risk.
- MacDougall: Neuralink's first product is computer control for quadriplegic people, not moving limbs.
- MacDougall: the FDA requires proof of safety in animals before human work.
- MacDougall: current technology reaches only the brain's surface; mood, appetite and sleep come later.
- MacDougall: a healthy person would want an implant once it beats typing or speech-to-text.
- MacDougall: drugs will likely do more than implants for boosting plasticity.
- Chichilnisky: today's retinal implants give blobs and streaks of light, not natural vision.
- Chichilnisky's plan: record the cells, calibrate each electrode, then stimulate cell types separately.
- Chichilnisky: augmentation arrives quickly once you build devices to restore senses.
- Chichilnisky: introduce any new signal very slowly.
- Halpern: deep brain stimulation detects a craving and delivers a brief pulse to disrupt it.
- Halpern's field is exploring non-invasive options because deep brain stimulation requires surgery.
- Zuckerberg: brain implants start in medicine; his consumer product is a wristband.
- Talk with a neurologist, neurosurgeon, ophthalmologist or psychiatrist about what is approved for your condition.
This is the short form. The full insight has every expert's reasoning, their own words and the sources.